Provided by Tiger Fintech (Singapore) Pte. Ltd.

MoonLake Immunotherapeutics

51.89
-0.8700-1.65%
Post-market: 51.890.00000.00%17:57 EDT
Volume:303.02K
Turnover:15.68M
Market Cap:3.30B
PE:-18.59
High:52.92
Open:52.92
Low:51.08
Close:52.76
Loading ...

Leerink Partners Keeps Their Buy Rating on MoonLake Immunotherapeutics (MLTX)

TIPRANKS
·
Yesterday

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Pacira Pharmaceuticals (PCRX), Ultragenyx Pharmaceutical (RARE) and MoonLake Immunotherapeutics (MLTX)

TIPRANKS
·
Yesterday

RBC Capital Sticks to Their Buy Rating for MoonLake Immunotherapeutics (MLTX)

TIPRANKS
·
Yesterday

MoonLake Immunotherapeutics: Buy Rating Driven by Promising SLK Phase 3 Data and Strong Financial Position

TIPRANKS
·
05 Aug

Clear Street Sticks to Their Buy Rating for MoonLake Immunotherapeutics (MLTX)

TIPRANKS
·
05 Aug

Earnings Flash (MLTX) MoonLake Immunotherapeutics Posts Q2 Net Loss $0.87 a Share, vs. FactSet Est of $0.68 Loss

MT Newswires Live
·
05 Aug

MoonLake Q2 2025 EPS $(0.87) Misses $(0.72) Estimate

Benzinga
·
05 Aug

MoonLake Immunotherapeutics reports Q2 EPS (87c), consensus (76c)

TIPRANKS
·
05 Aug

MoonLake Immunotherapeutics Reports Q2 2025 Financial Results; R&D Expenses Rise Significantly, Strong Cash Position Maintained

Reuters
·
05 Aug

MoonLake Immunotherapeutics - Phase 3 Vela Program in Hs on Track for Sept 2025 Primary Endpoint Readout

THOMSON REUTERS
·
05 Aug

MoonLake Immunotherapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update

GlobeNewswire
·
05 Aug

MoonLake Immunotherapeutics participates in a conference call with Clear Street

TIPRANKS
·
02 Aug

MoonLake Immunotherapeutics: Strategic Leadership Transition and Promising Clinical Progress Drive Buy Rating

TIPRANKS
·
01 Aug

Promising Outlook for MoonLake Immunotherapeutics: Buy Rating Backed by Strong Position in Hidradenitis Suppurativa Treatment

TIPRANKS
·
29 Jul

Guggenheim Reaffirms Their Buy Rating on MoonLake Immunotherapeutics (MLTX)

TIPRANKS
·
29 Jul

MoonLake initiated with a Neutral at Rothschild & Co Redburn

TIPRANKS
·
28 Jul

MoonLake Immunotherapeutics Director Makes a Major Stock Move!

TIPRANKS
·
08 Jul

Moonlake Immunotherapeutics Held Annual General Meeting of Shareholders

Reuters
·
07 Jun

Post-Bell | U.S. Stocks End Higher; Nvidia Gains 3%; Dollar General Jumps 16%; CoreWeave Surges 25%

Tiger Newspress
·
04 Jun

MoonLake Immunotherap Price Target Maintained With a $67.00/Share by RBC Capital

Dow Jones
·
03 Jun